Envoy Medical, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Envoy Medical, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $241.0K | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $225.0K | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $316.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $237.0K | Apr 1, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.76M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($20.80M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($29.92M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($15.92M) | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $1.38M | Apr 3, 2023 |
| FY2022 | Dec 31, 2021 | ($251.6K) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($701) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.27M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($19.26M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($18.36M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($8.71M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.20M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($701) | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.49M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $10.18M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $8.96M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.98M | Apr 1, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $7.28M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $2.59M | Apr 1, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.20M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($17.95M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($17.09M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($8.81M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.24M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $179.0K | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $980.0K | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $153.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $218.0K | Apr 1, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.56M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $11.54M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $8.27M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.56M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $426.90M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $120.0K | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.33M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $30.38M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $10.05M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $38.75M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $38.62M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $95.7K | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.16M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($18.84M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2023 | ($1.78M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2022 | ($36.20M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($44.96M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $24.3K | Apr 3, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($313.40M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($284.73M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($257.26M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($225.99M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($36.71M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($701) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $4.22M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $183.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $149.8K | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $25.0K | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 19.55M | Apr 1, 2024 |